Status:
TERMINATED
Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer
Lead Sponsor:
Steba Biotech S.A.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The aim of this study is to determine the dose of WST11 and light energy necessary to obtain desobstruction of the bronchial lumen using Vascular Targeted Photodynamic therapy in obstructive Non-Small...
Detailed Description
This study is designed as a multicentre, exploratory phase IIa, open label, single intravenous (IV) dose, escalating treatment regimen (Treatment regimen = a single dose of WST11 associated with a par...
Eligibility Criteria
Inclusion
- Histologically proven lung cancer
- Inoperable
- Non-Small Cell Cancer
- Partial or total bronchial obstruction responsible for functional signs
- T1 to T4, N0-N3, M0-M1
- Patients with functional signs: hemoptysis, infection, cough and, above all, dyspnea
- Contralateral metastases not representing a contraindication insofar as they do not represent a risk of impairment of respiratory function during treatment
- The Karnofsky index should be greater than or equal to 40
- Patients should agree to and tolerate repeated bronchial endoscopy (a disadvantage of all endoscopic treatments)
- Male or female patients aged over 18 years, female patients should not be pregnant (menopause or contraception)
- Patients should have given their written consent to take part in the study
Exclusion
- Tracheal lesions and lesions affecting the carina tracheae
- Patients with painful bone metastases (not an absolute criterion since the extent of dyspnea is the decisive element)
- Patients with brain metastases
- Patients having undergone pneumonectomy
- Patients undergoing chemotherapy or radiotherapy or having undergone chemotherapy less than 4 weeks before the procedure or radiotherapy less than 4 weeks before the procedure
- Patients with risk of large vessel erosion or perforation resulting from lesion topography
- In case of allergy to the photosensitizer
- Leukopenia (WBC\<2000), Thrombocytopenia (\< 100 000), PT \> 1.5 normal, Fibrinogen \< 2g/l, a PTT \> 1.5 ULN (Upper Limit of Normal)
- Renal insufficiency
- Hepatic insufficiency
- Patients having already received 70 Gy on the lesion
- Existing tracheoesophageal or bronchoesophageal fistula
- Emergency treatment of patients with severe acute respiratory distress caused by an obstructing endobronchial lesion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00974662
Start Date
September 1 2009
End Date
December 1 2011
Last Update
April 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Foch
Suresnes, France